What is HC Wainwright’s Estimate for Evolus FY2029 Earnings?

Evolus, Inc. (NASDAQ:EOLS) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Evolus in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst D. Tsao expects that the company will post earnings of $4.43 per share for the year. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.63) per share.

Separately, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Tuesday.

Evolus Stock Up 1.5 %

Shares of EOLS stock opened at $14.23 on Thursday. Evolus has a 1-year low of $9.25 and a 1-year high of $17.82. The stock’s fifty day moving average price is $11.79 and its 200 day moving average price is $13.77. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a market cap of $901.04 million, a price-to-earnings ratio of -15.64 and a beta of 1.32.

Institutional Trading of Evolus

Large investors have recently added to or reduced their stakes in the company. Barclays PLC grew its stake in Evolus by 268.0% during the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after purchasing an additional 68,213 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Evolus by 173.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after purchasing an additional 265,635 shares during the last quarter. Armistice Capital LLC acquired a new position in shares of Evolus in the 2nd quarter valued at about $3,906,000. Jane Street Group LLC lifted its holdings in shares of Evolus by 47.0% in the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after buying an additional 29,396 shares during the period. Finally, Lord Abbett & CO. LLC lifted its holdings in shares of Evolus by 23.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after buying an additional 188,685 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.